Full Text:   <1508>

CLC number: R737

On-line Access: 

Received: 2008-05-28

Revision Accepted: 2008-11-30

Crosschecked: 2008-12-02

Cited: 6

Clicked: 4607

Citations:  Bibtex RefMan EndNote GB/T7714

-   Go to

Article info.
1. Reference List
Open peer comments

Journal of Zhejiang University SCIENCE B 2009 Vol.10 No.3 P.159~167

http://doi.org/10.1631/jzus.B0820175


Anti-angiogenesis effect of generation 4 polyamidoamine/vascular endothelial growth factor antisense oligodeoxynucleotide on breast cancer in vitro


Author(s):  Shan-zhi GU, Xin-han ZHAO, Ling-xiao ZHANG, Li LI, Zhi-yu WANG, Min MENG, Gai-li AN

Affiliation(s):  MOE Key Laboratory of Environment and Genes Related to Diseases; more

Corresponding email(s):   zhaoxinhan@mail.xjtu.edu.cn

Key Words:  Breast cancer, Vascular endothelial growth factor (VEGF), VEGF mRNA, Generation 4 polyamidoamine (G4PAMAM), Generation 4 polyamidoamine/vascular endothelial growth factor antisense oligodeoxynucleotide (G4PAMAM/VEGFASODN), Vascular endothelial cell


Share this article to: More |Next Article >>>

Shan-zhi GU, Xin-han ZHAO, Ling-xiao ZHANG, Li LI, Zhi-yu WANG, Min MENG, Gai-li AN. Anti-angiogenesis effect of generation 4 polyamidoamine/vascular endothelial growth factor antisense oligodeoxynucleotide on breast cancer in vitro[J]. Journal of Zhejiang University Science B, 2009, 10(3): 159~167.

@article{title="Anti-angiogenesis effect of generation 4 polyamidoamine/vascular endothelial growth factor antisense oligodeoxynucleotide on breast cancer in vitro",
author="Shan-zhi GU, Xin-han ZHAO, Ling-xiao ZHANG, Li LI, Zhi-yu WANG, Min MENG, Gai-li AN",
journal="Journal of Zhejiang University Science B",
volume="10",
number="3",
pages="159~167",
year="2009",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B0820175"
}

%0 Journal Article
%T Anti-angiogenesis effect of generation 4 polyamidoamine/vascular endothelial growth factor antisense oligodeoxynucleotide on breast cancer in vitro
%A Shan-zhi GU
%A Xin-han ZHAO
%A Ling-xiao ZHANG
%A Li LI
%A Zhi-yu WANG
%A Min MENG
%A Gai-li AN
%J Journal of Zhejiang University SCIENCE B
%V 10
%N 3
%P 159~167
%@ 1673-1581
%D 2009
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B0820175

TY - JOUR
T1 - Anti-angiogenesis effect of generation 4 polyamidoamine/vascular endothelial growth factor antisense oligodeoxynucleotide on breast cancer in vitro
A1 - Shan-zhi GU
A1 - Xin-han ZHAO
A1 - Ling-xiao ZHANG
A1 - Li LI
A1 - Zhi-yu WANG
A1 - Min MENG
A1 - Gai-li AN
J0 - Journal of Zhejiang University Science B
VL - 10
IS - 3
SP - 159
EP - 167
%@ 1673-1581
Y1 - 2009
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B0820175


Abstract: 
Objective: To study the effects of the generation 4 polyamidoamine/vascular endothelial growth factor antisense oligodeoxynucleotide (G4PAMAM/VEGFASODN) compound on the expressions of vascular endothelial growth factor (VEGF) and its mRNA of breast cancer cells and on the inhibition of vascular endothelial cells. Methods: We examined the morphology of G4PAMAM/VEGFASODN compound and its pH stability, in vitro transfection efficiency and toxicity, and the expressions of VEGF and its mRNA. Methyl thiazolyl tetrazolium assay was used to detect the inhibitory function of the compound on vascular endothelial cells. Results: The compound was about 10 nm in diameter and was homogeneously netlike. From pH 5 to 10, it showed quite a buffered ability. The 48-h transfection rate in the charge ratio of 1:40 was 98.76%, significantly higher than that of the liposome group (P<0.05). None of the transfection products showed obvious toxicity on the cells. The expressions of both VEGF protein and its mRNA after G4PAMAM/VEGFASODN transfection decreased markedly. Conclusion: With a low toxicity, high safety, and high transfection rate, G4PAMAM/VEGFASODN could be a promising gene vector. Specifically, it inhibits VEGF gene expression efficiently, laying a basis for further in vivo animal studies.

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1] Alton, E., 2007. Progress and prospects: gene therapy clinical trials (part 1). Gene Ther., 14(20):1439-1447.

[2] Bertolini, F., Mancuso, P., Shaked, Y., Kerbel, R.S., 2007. Molecular and cellular biomarkers for angiogenesis in clinical oncology. Drug Discov. Today, 12(19-20):806-812.

[3] Devarakonda, B., Otto, D.P., Judefeind, A., Hill, R.A., de Villiers, M.M., 2007. Effect of pH on the solubility and release of furosemide from polyamidoamine (PAMAM) dendrimer complexes. Int. J. Pharm., 345(1-2):142-153.

[4] Edelstein, M.L., Abedi, M.R., Wixon, J., 2007. Gene therapy clinical trials worldwide to 2007—an update. J. Gene Med., 9(10):833-842.

[5] Esfand, R., Tomalia, D.A., 2001. Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov. Today, 6(8): 427-436.

[6] Flotte, T.R., 2007. Gene therapy: the first two decades and the current state-of-the-art. J. Cell. Physiol., 213(2):301-305.

[7] Guo, C., Wang, H., Lin, Y., Cai, Q., 2004. Application of Starburst (TM) PAMAM dendrimers as DNA carriers in vitro. Prog. Biochem. Biophys., 31(9):804-811.

[8] Hattori, Y., Ding, W., Maitani, Y., 2007. Highly efficient cationic hydroxyethylated cholesterol-based nanoparticle-mediated gene transfer in vivo and in vitro in prostate carcinoma PC-3 cells. Journal of Controlled Release, 120(1-2):122-130.

[9] Hayes, D.F., Miller, K., Sledge, G., 2007. Angiogenesis as targeted breast cancer therapy. Breast, 16(2):17-19.

[10] Miller, A.D., 2003. The problem with cationic liposome/ micelle-based non-viral vector systems for gene therapy. Curr. Med. Chem., 10(14):1195-1211.

[11] Mo, Z., Liu, Y., Chen, H., Li, H., Sun, Y., 2007. Preparation and molecular dynamics simulation of Sm/PAMAM nano-composite. Rare Metal. Mat. Eng., 36(1):32-36 (in Chinese).

[12] Schiavone, N., Donnini, M., Nicolin, A., Capaccioli, S., 2004. Antisense oligonucleotide drug design. Curr. Pharm. Design, 10(7):769-784.

[13] Vattemi, E., Claudio, P.P., 2007. Advances and perspectives in gene-based therapy for breast cancer. Drug Future, 32(6):507-516.

[14] Wang, Y., Boros, P., Liu, J., Qin, L., Bai, Y., Bielinska, A.U., Kukowska-Latallo, J.F., Baker, J.R., Bromberg, J.S., 2000. DNA/dendrimer complexes mediate gene transfer into murine cardiac transplants ex vivo. Mol. Ther., 2(6): 602-608.

[15] Yoo, H., Juliano, R.L., 2000. Enhanced delivery of antisense oligonucleotides with fluorophore-conjugated PAMAM dendrimers. Nucleic Acids Res., 28(21):4225-4231.

[16] Zelnak, A.B., O′Regan, R.M., 2007. Targeting angiogenesis in advanced breast cancer. BioDrugs, 21(4):209-214.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - Journal of Zhejiang University-SCIENCE